Clinical Trials
Dry Age Related Macular Degeneration
Active Studies
AMEND (Smilebiotek)
A phase 2, double-masked, randomized, placebo-controlled, dose-response study assessing the safety and efficacy of QA102 in subjects with dry age-related macular degeneration (AMD).
GALE (Apellis)
A phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of Pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration.
HONU (Roche/Genentech)
A multicenter, prospective, observational study of the progression of intermediate age-related macular degeneration.
iGAIN (Complement Therapeutics)
A MULTICENTRE, NATURAL HISTORY, NON-INTERVENTIONAL STUDY EVALUATING BIOMARKERS IN PARTICIPANTS WITH GEOGRAPHIC ATROPHY(GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD)
ONWARD (Alexion)
A Phase 2, DoubleMasked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
SIGLEC (Aviceda)
A Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration.
Completed Studies
ARCHER (Annexon)
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
BEACON (Allergan)
A 2 year, phase 2 study on the safety and efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with geography atrophy secondary to age-related macular degeneration.CATALINA (NGM Biopharmaceuticals)
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
DERBY (Apellis)
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
GALLEGO (Genentech)
A 18-month, phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration.
GATHER 2 (Iveric)
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA™ (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION.
GR39821 (Genentech)
A phase 1, open-label, single-dose, dose-escalation, and multiple-dose study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to macular degeneration.GR42163 (Genentech)
A PHASE Ia, MULTICENTER, OPEN-LABEL, SINGLE-DOSE, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVITREAL INJECTIONS OF RO7303359 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
ICON (Pfizer)
A 1 year Phase 2 study examining a monoclonal antibody to decrease the amount of drusen in the eyes seen in people with Dry AMD with an intravenous infusion.
OMASPECT (Genentech)
A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a roche-sponsored study.PREVENT IIT (NCRVA & Genentech)
A 2 year investigator initiated study on prophylactic Ranibizumab for exudative age-related macular degeneration (AMD) in vulnerable eyes with Non exudative AMD Trial.SEATTLE (Acucela)
A 2 year Phase 2/3 study which aims to reduce the rate of Dry AMD progression with the use of an pill.
SPECTRI (Genentech)
A 2 year, phase 3, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.TARGETing GA (Santen Inc.)
Non-interventional, cross-sectional study of Alu RNA measurement and complement factor genotyping of single nucleotide polymorphisms in the complement pathway in patients with geographic atrophy associated with dry age-related macular degeneration.ZIMURA (Ophthotech)
A 18-month, phase2B study on the safety and efficacy of Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration.